Bartonellosis (Carrion's Disease)

Comprehensive Clinical Guide: Bartonellosis (Carrion’s Disease)

1. Introduction and Clinical Overview

Bartonellosis, clinically referred to as Carrion’s Disease, is a complex, biphasic, infectious disease caused by the gram-negative, facultative intracellular bacterium Bartonella bacilliformis. Restricted geographically to the high-altitude Andean valleys of Peru, Ecuador, and Colombia, the disease is transmitted exclusively through the bite of infected female sandflies of the genus Lutzomyia.

Carrion’s Disease is historically significant and clinically unique due to its two distinct clinical phases: the acute hematic phase (Oroya Fever) and the chronic eruptive phase (Verruga Peruana). Understanding this pathology requires a deep appreciation for the interaction between the bacterium and human erythrocytes, leading to profound hemolytic anemia in the acute stage and endothelial cell proliferation in the chronic stage.

2. Etiology and Pathophysiology

The Pathogen: Bartonella bacilliformis

B. bacilliformis is a small, motile, aerobic, gram-negative coccobacillus. Its survival mechanism is highly specialized, involving the colonization of human red blood cells (RBCs) and endothelial cells.

Pathophysiological Mechanisms

The disease progression is defined by the pathogen's ability to manipulate host cell biology:

• Adherence: The bacteria use flagella to attach to the surface of erythrocytes.
• Invasion: The deforming protein (a major virulence factor) facilitates the internalization of the bacteria into the RBC.
• Hemolysis: The bacterium’s metabolic activity and the host's immune response (splenic clearance) lead to rapid destruction of infected erythrocytes, resulting in severe hemolytic anemia.
• Angiogenesis: During the chronic phase, the bacteria promote the expression of vascular endothelial growth factor (VEGF), leading to the formation of Verruga Peruana (Peruvian warts).

3. Clinical Staging and Presentation

Carrion’s Disease is characterized by a biphasic clinical course, often separated by a latent period.

Stage I: The Acute Hematic Phase (Oroya Fever)

This stage is characterized by high fever, severe malaise, and rapidly progressive anemia.
* Clinical Presentation:
* Fever: High-grade, often irregular.
* Anemia: Severe, symptomatic hemolytic anemia (hemoglobin levels can drop rapidly to <5 g/dL).
* Immunosuppression: Patients are highly susceptible to secondary infections, particularly Salmonella species.
* Neurological symptoms: Altered mental status, delirium, or coma in severe cases.
* Hepatomegaly and Lymphadenopathy: Common findings.

Stage II: The Chronic Eruptive Phase (Verruga Peruana)

This stage occurs weeks or months after the acute phase, although some patients may progress directly to this stage without a documented acute phase.
* Clinical Presentation:
* Miliary lesions: Small, red-purple papules (1–4 mm).
* Nodular lesions: Larger, deeper, and more friable vascular lesions.
* Mular lesions: Large, pedunculated, tumor-like masses that bleed easily.
* Distribution: Primarily on the extremities and face, but can involve mucous membranes.

4. Differential Diagnosis

Because the symptoms of Carrion’s disease are non-specific, it is frequently misdiagnosed in non-endemic settings.

5. Diagnostic Testing and Clinical Protocols

Diagnostic confirmation is essential for appropriate antibiotic therapy.

Key Diagnostic Modalities

1. Peripheral Blood Smear (Giemsa Stain): The gold standard for the acute phase. The bacterium is visualized attached to or inside erythrocytes.
2. Blood Culture: Highly specific but slow-growing. B. bacilliformis requires specialized media and prolonged incubation (up to 3-4 weeks).
3. Polymerase Chain Reaction (PCR): The most sensitive method for both phases, especially when bacterial load is low.
4. Serology (IFA/ELISA): Useful for epidemiological surveys and identifying past exposure, though cross-reactivity with other Bartonella species is possible.

6. Risks, Contraindications, and Management

Antibiotic Stewardship

• Acute Phase: Ciprofloxacin is the treatment of choice due to its excellent intracellular penetration. Chloramphenicol is an alternative, especially in cases of suspected secondary Salmonella superinfection.
• Chronic Phase: Rifampin or macrolides (e.g., Azithromycin) are often used to manage the eruptive lesions.

Risks and Complications

• Secondary Infection: Salmonella enterica is the most lethal complication during the acute phase.
• Severe Anemia: May require blood transfusion if hemodynamic instability is present.
• Jarisch-Herxheimer Reaction: A potential risk when initiating rapid bactericidal therapy.

7. Frequently Asked Questions (FAQ)

1. Is Carrion’s Disease contagious from person to person?

No. The disease is transmitted exclusively through the bite of the female Lutzomyia sandfly. There is no human-to-human transmission.

2. Can I get Carrion's Disease in the United States or Europe?

It is extremely unlikely. The disease is strictly endemic to high-altitude Andean regions (between 600 and 3,200 meters above sea level) in Peru, Ecuador, and Colombia.

3. Why is the mortality rate so high in the acute phase?

Mortality in the acute phase is primarily due to severe hemolytic anemia, multi-organ failure, and, most frequently, secondary opportunistic infections like salmonellosis.

4. What is the difference between Oroya Fever and Verruga Peruana?

Oroya Fever is the acute, systemic, hematologic phase. Verruga Peruana is the chronic, cutaneous, angiomatous phase. They are two manifestations of the same infection.

5. How long does it take for symptoms to appear?

The incubation period is typically 2–3 weeks, though it can range from 10 days to several months.

6. Do the skin lesions of Verruga Peruana leave scars?

Yes, the larger mular lesions often leave permanent scarring or skin discoloration after they heal, especially if they become ulcerated or infected.

7. Is there a vaccine for Bartonellosis?

Currently, there is no commercially available vaccine for Bartonella bacilliformis. Prevention relies on vector control and personal protection against sandfly bites.

8. Can I use penicillin to treat this disease?

No. B. bacilliformis is generally resistant to penicillin. Ciprofloxacin and Chloramphenicol are the standard clinical recommendations.

9. How do I prevent sandfly bites?

Use insect repellents containing DEET, wear long-sleeved clothing during dawn and dusk (when sandflies are most active), and utilize fine-mesh bed nets.

10. Does having the disease once provide immunity?

Partial immunity is developed after exposure, but re-infection is possible, particularly if the patient moves between different endemic valleys where different strains may exist.

8. Long-term Prognosis

The prognosis for treated patients is generally excellent. With timely antibiotic intervention, the severe hemolytic anemia of the acute phase can be reversed. In the chronic phase, the skin lesions typically regress with appropriate antibiotic therapy, although cosmetic scarring may persist. If left untreated, the acute phase carries a mortality rate of up to 40–80%, making early clinical recognition and public health surveillance in endemic regions vital.

Patients who recover from the acute phase are often monitored for the subsequent development of the chronic eruptive phase, ensuring that any emerging vascular lesions are managed promptly to prevent secondary bacterial infection or excessive bleeding.